Active, not recruitingPhase 2NCT04079712
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
Studying Neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Adel MandlYale University Cancer Center LAO
- Intervention
- Cabozantinib S-malate(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- University of Kansas Clinical Research Center, Fairway, Kansas, United States
- HaysMed, Hays, Kansas, United States
- Lawrence Memorial Hospital, Lawrence, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04079712 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06202066Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasRoswell Park Cancer Institute
- RECRUITINGNCT06282016Risk Factors for Neuroendocrine NeoplasmsBavarian Cancer Registry
- RECRUITINGPHASE2NCT07077551NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm TrialSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06276309Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine TumorsFujian Maternity and Child Health Hospital
- RECRUITINGPHASE3NCT05918302Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.Grupo Espanol de Tumores Neuroendocrinos
- RECRUITINGNCT06402695Observational Study on GEP-and Pulm-NET Treated at FPGFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE2NCT05879055A Study of PM8002 in Combination With Chemotherapy in Patients With NENBiotheus Inc.
- RECRUITINGNCT06337760YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.European Institute of Oncology